Litcius/Paper detail

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

Jonathan E. Rosenberg, Thomas Powles, Guru Sonpavde, Yohann Loriot, Ignacio Durán, J.-L. Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak

2023Annals of Oncology153 citationsDOIOpen Access PDF

Topics & Concepts

MedicineChemotherapyOncologyInternal medicineUrothelial carcinomaPhases of clinical researchCancerBladder cancerBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentRenal cell carcinoma treatment
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma | Litcius